Please note this page is no longer being updated. If you are a clinician, please refer to the Lancashire and South Cumbria Medicines Management Group website in the first instance for up to date information, or email blackpool.medicinesoptimisation@nhs.net.
Medicines play an important part in promoting wellbeing, preventing ill health and managing disease. More than 700million prescription items are dispensed in England each year with a cost approaching £8billion.
Medicines management can be defined in several ways:
- The clinical, cost-effective, safe and secure handling of medicines.
- A system of processes and behaviours that determines how medicines are used by the NHS and patients.
- Enabling people to make the best possible use of medicines.
Our goal is to achieve the best health outcomes for patients where medicines are involved.
Many decisions relating to medicines management on the Fylde Coast are made on a Lancashire and South Cumbria-wide basis by the Lancashire and South Cumbria Medicines Management Group (LSCMMG).
Further information on medicine guidelines, prescribing guidance, position statements and supporting documents, shared care guidelines and high-cost medicines can be found on the LSCMMG website.
Fylde Coast medicines RAG list
Anti-infective
Blood and nutrition
Gluten-free
Name | Size | Hits |
---|---|---|
Gluten Free Foodstuffs | 0.2 MB | 410 |
Gluten-Free-Food-Products | 0.3 MB | 362 |
Sip feed
Name | Size | Hits |
---|---|---|
Clinical Need Thickeners Position Statement | 0.3 MB | 785 |
Oral Nutritional Supplements (ONS) in care and nursing homes | 0.2 MB | 579 |
Position Statement Sip Feeds | 0.4 MB | 423 |
SIP Feeds | 0.1 MB | 495 |
DVT/VTE/PE
Name | Size | Hits |
---|---|---|
Dalteparin SCG 2018 | 0.2 MB | 572 |
Rivaroxaban-10mg-for-DVT-and-PE-and-extended-use | 0.1 MB | 340 |
Vitamin D
Vitamins and minerals
Cardiovascular system
Ear, nose and oropharynx
Endocrine system
Blood glucose meters and strips (under review)
Name | Size | Hits |
---|---|---|
Blood glucose meters and test strips Type 2 Diabetes (Blackpool) | 0.5 MB | 2091 |
Blood Glucose meters and test strips Type 2 Diabetes (Fylde and Wyre) | 1.2 MB | 163 |
Diabetes
Name | Size | Hits |
---|---|---|
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus | 0.3 MB | 409 |
Thyroid
Name | Size | Hits |
---|---|---|
Liothyronine position statement | 0.2 MB | 381 |
Eye
Gastro-intestinal system
Genito-urinary system
Gender dysphoria
Musculoskeletal system
Arthritis
Name | Size | Hits |
---|---|---|
Botulinum Toxin A for Spasticity and Contracture of the joint | 0.3 MB | 353 |
Second Line Anti-TNF For PsA | 0.2 MB | 343 |
DMARDs
Name | Size | Hits |
---|---|---|
Denosumab for GIO | 0.2 MB | 376 |
DMARDs shared care
Name | Size | Hits |
---|---|---|
azathioprinemercaptopurine-shared-care-guideline-version-21 | 0.2 MB | 95 |
Ciclosporin-SCG-Version | 0.2 MB | 125 |
Leflunomide-SCG-Version | 0.2 MB | 114 |
Methotrexate-SCG-Version | 0.2 MB | 145 |
Penicillamine-SCG-Version | 0.2 MB | 105 |
Sodium-Aurothiomalate-SCG-Version | 0.2 MB | 112 |
Sulfasalazine-SCG-Version | 0.2 MB | 120 |
Other MSK
Nervous system (pain management and psychotics)
Antipsychotic
Name | Size | Hits |
---|---|---|
Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections | 0.6 MB | 357 |
Guidance to support the implementation of the valproate PREVENT programme | 0.5 MB | 568 |
Dementia
Name | Size | Hits |
---|---|---|
Management-of-Behavioural-and-Psychological-Symptoms-of-Dementia-Primary-Care-Summary-Document | 0.2 MB | 431 |
Pain
Name | Size | Hits |
---|---|---|
Cannabis-based-medication-desk-guide-Nov-2018 December-Edit | 0.6 MB | 376 |
Clinical Need Soluble Analgesics | 0.5 MB | 1868 |
Position Statement OPIOID PRESCRIBING max dose Version 1.2 Nov 21 | 0.1 MB | 66 |
Chronic pain
Non-chronic pain
Respiratory system
Asthma
COPD
Inhaler techniques
E-cigarettes
Skin
Name | Size | Hits |
---|---|---|
Emollients and Sunscreens | 0.2 MB | 1012 |
Wound Care Formulary V4 April 2021 | 1.6 MB | 2193 |
Miscellaneous
Prescribing process
Other policies
Rebate policies
Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third-party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.
Fylde & Wyre Current Primary Care Rebate Schemes in place:
- Clenil Modulite (Beclometasone) – commenced July 2019
- Dabigatran (Pradaxa) – commenced November 2020
- Degarelix (Firmagon) – commenced September 2016
- Fostair NEXThaler – commenced May 2021
- Fostair pMDI – commenced July 2021
- Fencino (Fentanyl) – commenced April 2016
- Longtec – commenced July 2019
- Prostap (Leuprorelin) – commenced April 2020
- Rivaroxaban (Xarelto) – commenced October 2019
- Sereflo – commenced July 2019
- Toujeo (Insulin Glargine) – commenced July 2021
- Zacco (Clobazam) – commenced March 2021
Blackpool Current Primary Care Rebate Schemes in place:
- Clenil Modulite (Beclometasone) – commenced July 2019
- Dabigatran (Pradaxa) – commenced November 2020
- Degarelix (Firmagon) – commenced September 2016
- Fostair NEXThaler – commenced May 2021
- Fostair pMDI – commenced July 2021
- Fencino (Fentanyl) – commenced October 2018
- Longtec – commenced July 2019
- Prostap (Leuprorelin) – commenced April 2020
- Rivaroxaban (Xarelto) – commenced July 2019
- Sereflo – commenced July 2019
- Toujeo (Insulin Glargine) – commenced July 2021
- Zacco (Clobazam) – commenced March 2021
Care homes
If you can’t find what you are looking for and think it was once listed in these pages, try the LSCMMG or our files archive